Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States.
University of Michigan, Medical School, Ann Arbor, Michigan, United States.
Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):5. doi: 10.1167/iovs.65.6.5.
The purpose of this study was to evaluate self-reported functional vision (FV) and the impact of vision loss in patients with USH2A-associated retinal degeneration using a patient-reported outcome (PRO) measure, the Michigan Retinal Degeneration Questionnaire (MRDQ), to correlate MRDQ scores with well-established visual function measurements.
An observational cross-sectional study (n = 93) of participants who had Usher Syndrome Type 2 (USH2, n = 55) or autosomal recessive non-syndromic retinitis pigmentosa (ARRP; n = 38) associated with biallelic variants in the USH2A gene.
The study protocol was approved by all ethics boards and informed consent was obtained from each participant. Participants completed the MRDQ at the 48-month study follow-up visit. Disease duration was self-reported by participants. One-way ANOVA was used to compare subgroups (clinical diagnosis, age, disease duration, and full-field stimulus threshold [FST] Blue-Red mediation) on mean scores per domain. Spearman correlation coefficients were used to assess associations between MRDQ domains and visual/retinal function assessments.
Of the study sample, 58% were female participants and the median disease duration was 13 years. MRDQ domains were sensitive to differences between subgroups of clinical diagnosis, age, disease duration, and FST Blue-Red mediation. MRDQ domains correlated with static perimetry, microperimetry, full-field stimulus testing, and best-corrected visual acuity (BCVA).
Self-reported FV measured by the MRDQ, when applied to USH2 and ARRP participants, had good distributional characteristics and correlated well with visual function tests. MRDQ adds a new dimension of understanding on vision-related functioning and establishes this PRO tool as an informative measure in evaluating USH2A outcomes.
本研究旨在评估使用患者报告结局(PRO)测量工具——密歇根视网膜变性问卷(MRDQ)评估 USH2A 相关视网膜变性患者的自我报告的功能性视力(FV)和视力丧失的影响,并将 MRDQ 评分与既定的视觉功能测量方法相关联。
这是一项针对具有双等位基因突变 USH2A 基因的 2 型 Usher 综合征(USH2,n=55)或常染色体隐性非综合征性视网膜色素变性(ARRP,n=38)患者的观察性横断面研究(n=93)。
本研究方案获得了所有伦理委员会的批准,并获得了每位参与者的知情同意。参与者在 48 个月的研究随访时完成了 MRDQ。疾病持续时间由参与者自行报告。采用单因素方差分析比较各亚组(临床诊断、年龄、疾病持续时间和全视野刺激阈值 [FST] 蓝-红中介)的各领域平均得分。采用 Spearman 相关系数评估 MRDQ 各领域与视觉/视网膜功能评估之间的相关性。
在研究样本中,58%为女性参与者,中位疾病持续时间为 13 年。MRDQ 各领域对临床诊断、年龄、疾病持续时间和 FST 蓝-红中介的亚组差异敏感。MRDQ 各领域与静态视野计、微视野计、全视野刺激测试和最佳矫正视力(BCVA)相关。
当应用于 USH2 和 ARRP 参与者时,MRDQ 测量的自我报告 FV 具有良好的分布特征,与视觉功能测试相关性良好。MRDQ 提供了对与视觉相关的功能的新的理解维度,并确立了这种 PRO 工具作为评估 USH2A 结果的一种有价值的测量方法。